



1600

DTOS Rec'd PCT/PTO

PCT  
12 AUG 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1638

In re Patent Application of

LERCHL et al

Atty. Ref.: 3557-11

Serial No. 10/088,027

Group:

National Phase of: PCT/EP00/09245

International Filing Date: 21 September 2000

RECEIVED

Filed: March 14, 2002

Examiner: SEP 09 2002

For: GMP SYNTHETASE DERIVED FROM PLANTS

TECH CENTER 1600/2900

\* \* \* \* \*

August 12, 2002

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**SUBMISSION**

Submitted herewith is an English translation of the International Preliminary

Examination Report received in connection with PCT/EP00/09245.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

05. JUNI 2002

527

N2 -

ID -



## PCT

NOTIFICATION OF TRANSMITTAL  
OF COPIES OF TRANSLATION  
OF THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT

(PCT Rule 72.2)

From the INTERNATIONAL BUREAU

To:

BASF AKTIENGESELLSCHAFT  
67056 Ludwigshafen  
ALLEMAGNE

AST

Date of mailing (day/month/year)

22 May 2002 (22.05.02)

Applicant's or agent's file reference

0050/050777

## IMPORTANT NOTIFICATION

International application No.

PCT/EP00/09245 ✓

International filing date (day/month/year)

21 September 2000 (21.09.00) ✓

Applicant

BASF AKTIENGESELLSCHAFT et al

## 1. Transmittal of the translation to the applicant.

The International Bureau transmits herewith a copy of the English translation made by the International Bureau of the international preliminary examination report established by the International Preliminary Examining Authority.

## 2. Transmittal of the copy of the translation to the elected Offices.

The International Bureau notifies the applicant that copies of that translation have been transmitted to the following elected Offices requiring such translation:

CA,CN,JP,KP,KR,US

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

The following elected Offices, having waived the requirement for such a transmittal at this time, will receive copies of that translation from the International Bureau only upon their request:

AP,EA,EP,AE,AG,AL,AM,AT,AU,AZ,BA,BB,BG,BR,BY,BZ,CH,CR,CU,CZ,DE,DK,DM,DZ,EE,ES,FI,GB,GD,GE,GH,GM,HR,HU,ID,IL,IN,IS,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MA,MD,MG,MK,MN,MW,MX,MZ,NO,NZ,PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,TZ,UA,UG,UZ,VN,YU,ZA,ZW,OA

## 3. Reminder regarding translation into (one of) the official language(s) of the elected Office(s).

The applicant is reminded that, where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report.

It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned (Rule 74.1). See Volume II of the PCT Applicant's Guide for further details.

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Authorized officer

Olivia TEEY

Facsimile No. (41-22) 740.14.35

Telephone No. (41-22) 338.83.38

ISF

Translation

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 0050/050777	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP00/09245	International filing date ( <i>day/month/year</i> ) 21 September 2000 (21.09.00)	Priority date ( <i>day/month/year</i> ) 01 October 1999 (01.10.99)
International Patent Classification (IPC) or national classification and IPC C12N 15/82		
Applicant BASF AKTIENGESELLSCHAFT		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 7 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.

RECEIVED

3. This report contains indications relating to the following items:

SEP 09 2002

TECH CENTER 1600/2900

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 21 April 2001 (21.04.01)	Date of completion of this report 06 February 2002 (06.02.2002)
Name and mailing address of the IPEA/EP	Authorized officer
Facsimile No.	Telephone No.

Form PCT/IPEA/409 (cover sheet) (January 1994)

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT


International application No.

PCT/EP00/09245

## I. Basis of the report

1. This report has been drawn on the basis of (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

- ☒ the international application as originally filed.
- ☐ the description, pages 1-25, as originally filed,  
 pages \_\_\_\_\_, filed with the demand,  
 pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_,  
 pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_.
- ☐ the claims, Nos. 1,3-16, as originally filed,  
 Nos. \_\_\_\_\_, as amended under Article 19,  
 Nos. \_\_\_\_\_, filed with the demand,  
 Nos. 2, filed with the letter of 21 December 2001 (21.12.2001),  
 Nos. \_\_\_\_\_, filed with the letter of \_\_\_\_\_.
- ☐ the drawings, sheets/fig 1/4-4/4, as originally filed,  
 sheets/fig \_\_\_\_\_, filed with the demand,  
 sheets/fig \_\_\_\_\_, filed with the letter of \_\_\_\_\_,  
 sheets/fig \_\_\_\_\_, filed with the letter of \_\_\_\_\_.



2. The amendments have resulted in the cancellation of:

- ☐ the description, pages \_\_\_\_\_
- ☐ the claims, Nos. \_\_\_\_\_
- ☐ the drawings, sheets/fig \_\_\_\_\_

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).

4. Additional observations, if necessary:

RECEIVED

SEP 0 9 2002

TECH CENTER 1600/2900

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International Application No.

PCT/EP 00/09245

## Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: III.1

Claim 16 is unclear to such an extent that no opinion can be established (PCT Article 6). The "compound" mentioned in the method described is characterized only by functional criteria. It therefore cannot be determined whether the above claim would also encompass known methods for eliminating plant growth.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.  
PCT/EP 00/09245

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Claims	1-12	YES
	Claims		NO
Inventive step (IS)	Claims	7, 11, 12	YES
	Claims	1-6, 8, 9, 10	NO
Industrial applicability (IA)	Claims	1-12	YES
	Claims		NO

### 2. Citations and explanations

This report makes reference to the following documents:

- D1: DATABASE EMBL [Online] ACCESSION NO: F14426, 20 July 1995 (1995-07-20) MORRIS, P.C., ET AL.: 'A. thaliana transcribed sequence; clone YAY969; 3' end; similar to GMP Synthase; Saccharomyces cerevisiae.'  
XP002167639
- D6: US-A-5 780 254 (SUBRAMANIAN VENKITESWARAN ET AL), 14 July 1998 (1998-07-14)
- D7: US-A-5 780 253 (SUBRAMANIAN VENKITESWARAN ET AL), 14 July 1998 (1998-07-14)
- D8: WO-A-95/27789 (SYNTEX INC), 19 October 1995 (1995-10-19)
- D9: WO-A-98/10074 (BASF AG; LERCHL JENS (DE); SONNEWALD UWE (DE); BADUR RALF (DE); SC), 12 March 1998 (1998-03-12).

#### 1. Inventive step (PCT Article 33(3))

1.1 Document D1 was identified as closest prior art with respect to the subject matter of present Claim 1. The present application differs from D1 in that its object is to provide a complete coding sequence of a GMP synthetase

from other plants (*Nicotiana tabacum* and *Physcomitrella patens*).

Document D1 states that its partial sequence from *Arabidopsis thaliana* is similar to a GMP synthetase from *S. cerevisiae*. In the prior art GMP synthetases are referred to as targets for herbicidal action (see, for example, D6: column 3, lines 58 and 59; D7: column 1, lines 51-55; D9: page 1, lines 41-42 and Figure 1). For a person skilled in the art this teaching would be sufficient motivation to determine the full sequence of the clone described in D1 and, with the aid of known methods (e.g. PCR, library screening), use same also to isolate coding sequences for GMP synthetases from other plants. In view of the prior art a person skilled in the art could reasonably have expected to be successful in his attempt.

The expression of such a sequence in prokaryotic or eukaryotic cells (Claim 6) with the aim of synthesizing a plant GMP synthetase likewise represents routine practice and hence cannot substantiate an inventive step.

The use of recombinant GMP synthetases in activity tests for the identification of inhibitors is likewise known in the prior art (e.g. D8: Screening for inhibitors of human GMP-synthetase, Examples 5 and 6).

Claims 1-6, 8 and 9 are ~~therefore~~ not inventive with respect to D1, combined with D6, D7, D8 or D9 (PCT Article 33(3)).

**1.2** Claim 10 discloses a method for identifying substances with herbicidal action which inhibit GMP synthetase activity in plants. However, Claim 10 is not

restricted to the sequences described in the application or variants thereof, but relates generally to a "DNA sequence coding for an enzyme with GMP synthetase activity". This represents a purely conceptual wording of a screening method for GMP synthetase inhibitors with herbicidal action.

D9 describes the production of transgenic plants which overexpress the enzyme adenylosuccinate synthetase (ADSS). This overexpression results in resistance of the transgenic plants to ADSS inhibitors (page 9, line 45, to page 10, line 6). It is therefore obvious that such transgenic plants can also be used as negative controls in screening methods for identifying new inhibitors. D9 also points out that "some of the enzymes involved in purine biosynthesis [...] constitute potential points of attack for herbicidal substances" (page 1, lines 41 and 42).

The concept of overexpression of purine biosynthesis enzymes for the identification of inhibitors is therefore obvious and can consequently not be considered inventive.

Claim 10 is not inventive with respect to D9 (PCT Article 33(3)).

Moreover, Claim 10 is not sufficiently disclosed and supported by the description (PCT Articles 5 and 6). The present application discloses only methods based on the identified GMP synthetases but does not contain a basis for extension to all "DNA sequences coding for an enzyme with GMP synthetase action".

1.3 Claims 7, 11 and 12 relate to uses of the GMP synthetases identified in the application for the identification of inhibitors of said enzyme having a



herbicidal action.

Although the provision of the nucleotide or amino acid sequence of a plant GMP synthetase cannot be considered inventive per se (see 1.1), it was not obvious to use this sequence for the identification of GMP inhibitors with herbicidal action.

D6 and D7 disclose a method for identifying herbicides with targeted inhibition of GMP biosynthesis (D6 and D7, EXAMPLE 3). However, they do not clearly demonstrate the effect of the inhibitor mycophenolate on GMP synthase because two enzymes, that is IMP-dehydrogenase and GMP synthase, are potential targets of inhibition. It is therefore not obvious to a person skilled in the art that GMP synthetase is a suitable target for herbicides.

D9 likewise mentions GMP synthetase only in connection with other enzymes of purine biosynthesis without indicating which of these enzymes (apart from ADSS, whose suitability is demonstrated) would be especially suitable as herbicide target.

Claims 7, 11 and 12 are inventive (PCT Article 33(3)).